This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the first quarter.
Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 27.78% and 2.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Avanos Medical (AVNS) Stock Now
by Zacks Equity Research
Investor confidence is high in Avanos Medical (AVNS) stock, courtesy of its solid prospects.
Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.
Avanos Medical (AVNS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 27.27% and 0.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why You Should Retain Avanos Medical (AVNS) Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), courtesy of solid prospects.
Why Is Avanos Medical (AVNS) Up 3.7% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos Medical (AVNS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continued to gain from core Chronic Care segment in the third quarter.
Avanos Medical (AVNS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 50.00% and 11.94%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
Why Is Avanos Medical (AVNS) Up 5.7% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter results benefit from contribution from Chronic Care segment.
Avanos Medical (AVNS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 262.50% and 10.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Avanos Medical (AVNS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
Avanos Medical (AVNS) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, stiff competition remains a concern.
Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) first-quarter results benefit from segmental contribution.
Avanos Medical (AVNS) Lags Q1 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -5.88% and 4.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Avanos Medical Stock Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, weak performance at Acute Pain unit raises concern.
Why Is Avanos Medical (AVNS) Down 30.2% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Avanos Medical (AVNS) Stock Now
by Zacks Equity Research
Avanos (AVNS) gains from solid fourth-quarter show despite headwinds in the Acute Pain business.